Jamil Khurram reported option exercise involving 568 derivative units of GALECTIN THERAPEUTICS INC at $0.00 for $0 on May 26, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Medical Officer
Chief Medical Officer
Filed May 28, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
568Stock option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
40,057Direct
Trade date
May 26, 2026Option exercise
Filed
May 28, 2026, 9:13 AM ET2-day reporting delay
Accession
0001133416-26-000055Code M · Transaction 387230
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 26, 2026Option exercise568$1.23$698.64Trade 387228
May 26, 2026Sell568$3.10−$1,761.03Trade 387229
3 transaction rows in this filing. Joint filers share the same rows.

GALT price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
GALT · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −9.3%1w ago −19%1d ago −2.7%
Returns since7d −7.4%30d +94%90d +61%180d1y

Footnotes in full

F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F2: The shares were sold in multiple transactions at prices ranging from $3.00 to $3.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F3: The options vest as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026.